Recent articles
Here's Why Viking Therapeutics Rose as Much as 13.9% Today
A rival's setback is this small cap's gain, right?
Here's Why Tronox Gained as Much as 20.2% Today
The titanium dioxide manufacturer announced progress on its proposed acquisition of Cristal.
The 1 Stock I'd Buy Right Now
Most investors have probably never heard of this small-cap laboratory equipment supplier, but it reached an important inflection point in 2018.
Here's Why Coherus BioSciences Rose 48.7% in January
The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.
Here's Why Cara Therapeutics Stock Rose 17.3% in January
An important phase 3 clinical trial enrolled its last patient at the beginning of the year, which means top-line results could be right around the corner.
Here's Why CRISPR Therapeutics Rose 13.5% in January
The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.
Here's Why Flexion Therapeutics Rose 29.8% in January
The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
Here's Why Lexicon Pharmaceuticals Lost 28.8% in January
The company's lead drug candidate got thrown into a whirlwind of uncertainty.
2 Renewable Energy Stocks to Buy in February
Two well-managed renewable energy businesses are not getting much love from Wall Street right now, but the high-yield stocks are great long-term buys.
Here's Why Sage Therapeutics Gained 48.9% in January
The pharma company reported positive results from an important phase 3 trial.
Here's Why International Paper Rose 17.5% in January
The paper company recovered after an awful December and then proved Wall Street wrong with full-year 2018 operating results.
Will Pledges for 100% Carbon-Free Electricity Catch On in 2019?
One of America's largest electric utilities has committed to generating all of its electricity from zero-carbon sources by 2050. Will peers follow?
1 Dividend Stock to Buy in February
Wall Street soured on this water utility after it announced a massive acquisition in a new industry, but that could change when full-year 2018 earnings are reported.
Here's Why Genetic Testing Stocks Rose as Much as 31.8% in January
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
About to Buy Penny Stocks? Look at These 3 Companies First.
Also, never buy a penny stock.
Here's Why Fluidigm Rose as Much as 14.2% Today
The life sciences hardware provider reported full-year 2018 earnings results.
Here's Why Arrowhead Pharmaceuticals Gained as Much as 15.8% Today
The company announced fiscal first-quarter 2019 financial results and provided an update for the year ahead.
Here's Why Solid Biosciences Plunged Today
The company announced disappointing early results for a muscular dystrophy gene therapy.
Here's Why Renewable Energy Group Rose 12.4% in January
The biodiesel leader rebounded after a sour end to 2018, although investors have plenty to look forward to in the years ahead.
Here's Why Vanda Pharmaceuticals Is Sinking Today
The pharma company is taking the FDA to court over the regulator's insistence on animal testing.